This site is intended for healthcare professionals only.
This site is intended for healthcare professionals only.
Tuesday 11 November, 2025
at 16:00 GMT / 17:00 CET / 11:00 EST
75 minutes
The on-demand recording is available here.
Join Justin Gainor, Luis Paz-Ares, Lynette Sholl and Stevan Bradford for a discussion- and case-based-webinar exploring the latest in NTRK fusion-positive non-small cell lung cancer (NSCLC).
Learn how to:
This webinar is aimed at oncologists, pathologists, pulmonologists, nurses and nurse practitioners, and all other members of the MDT team managing NSCLC patients.
After taking part in this program, learners will be able to:
Dr. Justin Gainor is a thoracic medical oncologist and Director of the Center for Thoracic Cancers at Massachusetts General Hospital (MGH). He also serves as Director of Targeted Immunotherapy at the Henri and Belinda Termeer Center for Targeted Therapies at MGH and is Co-leader of the Dana-Farber/Harvard Cancer Center Lung Program. Dr. Gainor holds the academic title of Assistant Professor of Medicine at Harvard Medical School. His clinical and research interests focus on thoracic malignancies and immunotherapy.
Grants/Research Support: Takeda
Honoraria/Consulting Fees: AI Proteins, Amgen, Arcus, AstraZeneca, BeiGene, Blueprint Medicines, Bristol-Myers Squibb, Ellipses Pharma, Genentech/Roche, Ironwood Pharmaceuticals, iTeos, Jazz Pharmaceuticals, Karyopharm, Loxo/Lilly, Mariana Oncology (Curie), Merck, Merus Pharmaceuticals, Mirati, Novartis, Nuvalent, Pfizer, Sanofi, Silverback Therapeutics, Takeda, Tempus
Equity/Stock Ownership: AI Proteins
Spouse/Partner Employment: Ironwood Pharmaceuticals
Other Support: AI Proteins (Advisory Board, Consulting, Equity)
Dr. Luis Paz-Ares is Chair of the Medical Oncology Department at Hospital Universitario 12 de Octubre and Head of the Lung Cancer Unit at CNIO in Madrid. He also serves as Associate Professor at Universidad Complutense de Madrid and is a member of the Real Academia de Farmacia de Galicia.
He trained in medical oncology in Madrid and Glasgow, and has held leadership roles in oncology departments across Spain. His research focuses on lung cancer and the development of novel therapies, with over 340 publications in leading journals including NEJM, Lancet, and JCO. Dr. Paz-Ares has served on scientific committees for ASCO, ESMO, EORTC, and regulatory agencies including the Spanish Agency of Medicines and the European Medicines Agency. Dr. Paz-Ares is Chief Medical Officer of the Spanish Association Against Cancer (AECC), where he also serves on the Board.
Grants/Research Support (paid to institution): AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme (MSD), Pfizer, Roche
Honoraria/Consulting Fees: AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, BeOne, BeiGene, BMS, Boehringer Ingelheim, Daiichi Sankyo, Gilead, GSK, Janssen, Lilly, Medscape, Merck, Mirati, MSD, Novartis, Pharmamar, Pfizer, Regeneron, Roche/Genentech, Sanofi, Takeda
Speaker’s Bureau Participation: AbbVie, Amgen, AstraZeneca, BeiGene, BMS, Boehringer Ingelheim, Daiichi Sankyo, Lilly, Merck, MSD, Novartis, Pfizer, Pharmamar, Janssen, Regeneron, Roche
Equity/Stock Ownership: Altum Sequencing, Stab Therapeutics
Spouse/Partner Employment: Amgen, Astellas, Crinetics Pharmaceuticals, Esteve, HUTCHMED, Ipsen, ITM, Merck, Novartis, Pfizer, Roche, Sanofi, Servier
Dr. Lynette M. Sholl is a pathologist at Brigham and Women’s Hospital in Boston and Professor of Pathology at Harvard Medical School. She completed her medical school training at Stanford University School of Medicine, an internship in internal medicine at the Hospital of University of Pennsylvania, anatomic pathology residency and fellowship at Brigham and Women’s Hospital, and the molecular genetics pathology fellowship at the Harvard teaching hospitals. Her research interests include predictive tumor characterization and clinical validation of novel molecular and immunohistochemical tests for lung cancers. Dr. Sholl’s responsibilities include serving as the Division Chief for Molecular Diagnostics at Mass General Brigham and as Chief of the Pulmonary Pathology Service at Brigham and Women’s Hospital.
Grants/Research Support: Bristol Myers Squibb, Genentech
Honoraria/Consulting Fees: Genentech, Lilly
Stevan has worked in the industrial field for many years and is currently a shift coordinator at a steel mill, overseeing acid regeneration operations. He’s passionate about the outdoors and enjoys spending time in state parks, hiking, boating, fishing, and photography. His favourite quote is Emerson’s “In the woods we return to reason and faith”, which reflects his deep connection to nature and resilience through life’s challenges.
Nothing to disclose.
The NTRK fusion-positive NSCLC: perspectives from pathology, oncology and beyond, London, UK, United Kingdom 11/11/2025 – 11/11/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Springer Health+ IME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this activity for a maximum of 1.25 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program is aligned with Springer Medicine – an English-language, medical education platform provided by the Springer Nature Group. Springer Medicine supports doctors in their ongoing quest for optimal patient care, and delivers the latest evidence on new therapies, practice guidelines and news in easily digestible formats to keep healthcare professionals effortlessly up to date.
